A prospective identification and mechanistic evaluation of clinically significant drug–drug interactions in chronic kidney disease patients using the Micromedex® database

INTRODUCTION

Chronic kidney disease (CKD) represents a major global public health challenge, with a steadily increasing prevalence worldwide and a substantial contribution to cardiovascular morbidity, hospitalization, and premature mortality.^1-3 The rising burden of CKD is largely attributable to increasing rates of diabetes mellitus, hypertension, and population aging.

As kidney function declines, patients require long-term pharmacotherapy to manage associated comorbidities such as cardiovascular disease, anemia, and mineral and bone disorders.⁴ The complexity of pharmacotherapy in CKD inevitably results in polypharmacy, which is a principal determinant of drug–drug interactions (DDIs).⁵ Polypharmacy not only increases the likelihood of DDIs but also heightens the risk of adverse drug reactions, making safe prescribing a cornerstone of nephrology care.

Physiological changes accompanying CKD profoundly alter drug pharmacokinetics. Reduced glomerular filtration rate leads to impaired renal elimination of drugs and metabolites, while uremia alters plasma protein binding and drug distribution.⁶ Beyond renal clearance, uremic toxins and chronic inflammation downregulate hepatic and intestinal drug-metabolizing enzymes and transporters, particularly cytochrome P450 (CYP) isoenzymes.^7-9 Consequently, drugs primarily eliminated via hepatic pathways may exhibit altered pharmacokinetics in CKD.

Pharmacodynamic interactions are equally important. Drugs commonly prescribed in CKD—including diuretics, beta-blockers, calcium channel blockers, antiplatelet agents, anticoagulants, and immunosuppressants—often exert additive or synergistic effects on blood pressure, electrolyte balance, coagulation pathways, and cardiac conduction.^10,11 Such interactions may precipitate acute kidney injury, hyperkalemia, bleeding events, and arrhythmias, all of which are associated with poor prognosis in CKD patients.¹² Despite this recognized vulnerability, most available evidence is retrospective and lacks detailed mechanistic characterization.^13,14 Prospective pharmacovigilance studies are therefore essential to improve medication safety and guide rational prescribing in CKD.¹⁵

Despite the recognized risk of drug–drug interactions in CKD patients, there is limited prospective evidence using standardized and reproducible methods for identifying clinically significant DDIs. Many studies rely on retrospective data or lack mechanistic classification. Therefore, the present study aims to prospectively identify and mechanistically classify clinically significant DDIs in CKD patients using a standardized database (Micromedex®), with emphasis on severity grading and pharmacokinetic and pharmacodynamic mechanisms.

METHODS

Study design and setting

This prospective observational study was conducted at the Department of Nephrology, Muljibhai Patel Urological Hospital (MPUH), Nadiad, Gujarat, India, from September 2024 to January 2025. The study included adult patients (≥18 years) diagnosed with chronic kidney disease (stages 1–5) attending OPD, IPD, and dialysis units. A total sample size of 380 consecutive eligible patients was included based on availability during the defined study period (convenience sampling method). CKD staging was performed according to KDIGO guidelines. Estimated glomerular filtration rate (eGFR) was calculated using

Study population

Inclusion criteria

All gender patients, patients with comorbid conditions and all CKD patients above 18 years old were included.

Exclusion criteria

Pregnant and lactating women, the patient underwent renal transplantation and a patient admitted with acute kidney injury were excluded.

A total of 380 consecutive eligible CKD patients were included in the study.

Data collection

This observational study included 380 adults with CKD stages 1–5 attending a tertiary care hospital. Data were collected using a structured case record form. Demographic variables included age and sex. Clinical variables included CKD stage, age, gender, and current medication list.

Identification of drug–drug interactions

All prescribed medications were systematically screened for potential drug–drug interactions using the Micromedex® Drug Interaction Database. Each drug pair was independently evaluated to identify potential interactions. Duplicate interactions were excluded. Severity classification, mechanism (pharmacokinetic/ pharmacodynamic), and clinical effects were recorded based on the database evidence summaries.

Among all identified interactions, 61 DDIs were classified as clinically significant based on severity and potential to cause adverse clinical outcomes. These included 21 major, 28 moderate, and 12 minor interactions.

Definition of clinically significant DDIs

Associated with serious clinical outcomes, including bleeding, nephrotoxicity, electrolyte imbalance, or cardiac conduction abnormalities and required clinical intervention, such as dose adjustment, drug substitution, or enhanced monitoring

Classification of DDIs

Identified interactions were categorized based on severity (major, moderate, minor) and mechanism (pharmacokinetic or pharmacodynamic). Pharmacokinetic interactions were further evaluated for cytochrome P450 (CYP) enzyme and transporter involvement where applicable.

All identified DDIs were reproducible using the Micromedex® database criteria.

Ethical considerations

The study was submitted to the Muljibhai Patel Society for Research in Nephro-Urology Ethics Committee for Human Research for approval on 04 September 2024. The study was carried out to analyse prescription pattern and find out drug-drug interactions. The data was collected from the OPD, IPD, and dialysis unit. The main purpose of the study was well explained to the patients. Informed consent was maintained confidentially. After peer interviewing and reviewing, the study was approved by the ethics committee.

RESULTS

A total of 380 patients with CKD were included in the study. Using a standardized Micromedex® database screening approach and predefined criteria, 61 clinically significant drug–drug interactions were identified. All interactions were reproducible based on database classification.

As shown in Table 1, the study population (n=380) demonstrated a predominance of middle-aged and elderly patients. The largest proportion of patients belonged to the 41–60-year age group (44.7%), followed by those aged 61–80 years (30.5%). Younger adults aged 18–40 years accounted for 23.7%, while patients aged >80 years constituted only 1.1% of the cohort.

This distribution indicates that CKD and its associated pharmacotherapeutic complexity are most prevalent during middle and late adulthood, a period typically characterized by increasing comorbidities and medication burden, thereby predisposing patients to drug–drug interactions.

Demonstrates a clear male predominance, with 271 male patients (71.3%) compared to 109 female patients (28.7%). This gender imbalance may reflect higher prevalence of CKD-associated risk factors such as hypertension, diabetes mellitus, and cardiovascular disease among males in the studied population.

The predominance of male patients is clinically relevant, as sex-related differences in drug metabolism, body composition, and comorbidity patterns may further influence susceptibility to drug–drug interactions (Table 2).

The stage-wise distribution of CKD is presented in table 3. Advanced disease stages were highly prevalent, with stage 5 CKD accounting for 54.2% (n=206) of patients, followed by stage 4 CKD (19.2%, n=73). Early-stage CKD (stages 1 and 2 combined) constituted only 7.6% of the cohort. This skewed distribution toward advanced CKD reflects the tertiary care setting and underscores the complexity of pharmacotherapy in the study population. Advanced CKD is associated with reduced renal clearance, altered nonrenal drug metabolism, and a higher burden of comorbidities, all of which increase the likelihood of clinically significant DDIs.

Table 4 summarizes the cytochrome P450 (CYP) enzymes implicated in the identified clinically significant DDIs. CYP3A4 was the most frequently involved enzyme, followed by CYP2D6, CYP2C9, and CYP2C19. A substantial number of interactions were classified as not enzyme-mediated, reflecting pharmacodynamic mechanisms or pharmacokinetic interactions related to drug binding or altered absorption.

The predominance of CYP3A4-mediated interactions is clinically important, as this enzyme is responsible for the metabolism of numerous cardiovascular drugs, immunosuppressants, and statins commonly prescribed in CKD. Altered CYP activity in CKD may further amplify the clinical impact of such interactions (Table 4).

Moderate DDIs constituted the largest proportion, followed by major interactions. More than one-third of interactions were classified as major, highlighting a substantial risk of serious adverse outcomes in the CKD population. These findings confirm that a substantial proportion of identified interactions were clinically relevant according to predefined severity criteria (Table 5).

Pharmacodynamic mechanisms predominated among clinically significant DDIs, indicating that additive or synergistic physiological effects play a major role in interaction-related harm in CKD. The predominance of pharmacodynamic interactions highlights the importance of additive physiological effects in CKD patients receiving multiple medications (Table 6). The identified DDIs were consistent with known pharmacological mechanisms and database evidence, supporting the validity of the identification approach (Table 7-9).

DISCUSSION

This prospective observational study identified a substantial burden of clinically significant DDIs among patients with chronic kidney disease using a standardized Micromedex® database approach. The findings demonstrate that DDIs in CKD are common and can be systematically identified and categorized based on severity and mechanism. These findings are consistent with known pharmacological mechanisms and previously reported patterns in CKD populations.^1-3 Major DDIs were predominantly pharmacodynamic and involved drug classes commonly prescribed in CKD, including antiplatelet agents, anticoagulants, diuretics, cardiovascular drugs, and immunosuppressants. These interactions were associated with serious outcomes such as bleeding, nephrotoxicity, electrolyte disturbances, and cardiac conduction abnormalities, consistent with previous CKD studies.^5,12

Moderate DDIs exhibited heterogeneous mechanisms and clinical impact, often requiring dose adjustment or enhanced monitoring. Minor DDIs were largely pharmacokinetic and primarily affected drug absorption, particularly involving iron preparations, calcium salts, antacids, and thyroid medications.^10,11

A major strength of this study is the mechanistic differentiation between pharmacokinetic and pharmacodynamic interactions. Pharmacokinetic DDIs frequently involved CYP3A4, CYP2C9, CYP2D6, and CYP2C19. Altered CYP activity in CKD, driven by uremic toxins and inflammation, may amplify the clinical significance of these interactions even at standard doses. Pharmacodynamic interactions predominated in this study, reflecting the additive or synergistic effects of commonly co-prescribed drugs in CKD patients. Pharmacokinetic interactions were primarily mediated through CYP enzymes, particularly CYP3A4, highlighting the role of altered drug metabolism in this population.^7-9,11

The identified DDIs were largely predictable and manageable through appropriate clinical strategies such as dose adjustment, drug substitution, and monitoring. These findings emphasize the importance of structured medication review using electronic databases in routine clinical practice.^14,17

A key strength of this study is the use of a standardized and reproducible database (Micromedex®) for DDI identification, along with mechanistic classification and severity grading.

Limitations

This study has certain limitations. It was conducted at a single center, which may limit generalizability. Additionally, DDIs were identified based on database evidence rather than direct clinical outcome assessment. Future studies incorporating clinical endpoints are warranted.

CONCLUSION

Clinically significant drug–drug interactions are common in patients with chronic kidney disease and can be systematically identified using standardized tools such as the Micromedex® database. The majority of interactions are predictable and primarily pharmacodynamic in nature. These interactions can be effectively managed through appropriate strategies, including monitoring, dose adjustment, and avoidance of high-risk combinations. Incorporating structured DDI screening into routine clinical practice may enhance medication safety in this high-risk population.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. 1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260-72.
2. 2. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. GBD Chronic Kidney Disease Collaboration: Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(709-733):32061315.
3. 3. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.
4. 4. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members*. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Int Med. 2013;158(11):825-30.
5. 5. Manley HJ, Cannella CA, Bailie GR, Peter WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669-80.
6. 6. Harder S. Anticoagulant dosing in renal impairment. Phlebologie. 2015;44(06):316-9.
7. 7. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clinical Pharmacology & Therapeutics. 2008;83(6):898-903.
8. 8. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Therap. 2008;83(6):898-03.
9. 9. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003;16(1):45-50.
10. 10. Aronoff G. Drug prescribing in renal failure. ACP Press. 2007. Available at: https://books.google.com/books/about/Drug_Prescribing_in_Renal_Failure_5th_Ed.html?id=bH9omb-HKp4C. Accessed on 14 March 2026.
11. 11. Palmer BF, Clegg DJ. Electrolyte and acid–base disturbances in patients with diabetes mellitus. N Engl J Med. 2015;373(6):548-59.
12. 12. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531-48.
13. 13. Marquito AB, Fernandes NM, Colugnati FA, Paula RB. Identifying potential drug interactions in chronic kidney disease patients. Brazil J Nephrol. 2014;36:26-34.
14. 14. Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo). 2011;66(1):9-15.
15. 15. Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83-94.
16. 16. Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Society Nephrol. 2009;20(10):2269-76.
17. 17. World Health Organization. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala Monitoring Centre: World Health Organization. 2000. Available at: https://who-umc.org/media/1703/24747.pdf. Accessed on 14 March 2026.